DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award

0 Saves · 0 Shares · 0 Comments Discussion

Grant Name

Funder

Army Medical Research Acquisition Activity (AMRAA)

Department of Defense (DOD)

Country or Region

United States

Research Field

Science and Technology and other Research and Development

Deadline

Jul 10, 2024 12:00:00 AM EDT (Expired)

Grant Size

9800000

Contact Info

Danielle Reckley Grantor Help@eBRAP.org

Eligibility

Eligible Applicants:

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Grant Number

HT942524ALSRPTIA

Description

The FY24 ALSRP Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. Projects that focus primarily on pathophysiology of ALS without development of a therapy are outside the scope of this funding opportunity.

Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

The key elements of this award mechanism are:

Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS.

Impact: The FY24 TIA can be for a specific ALS subtype and does not have to broadly apply to all patients. Research should be non-incremental and pioneer transformative results that could lay the foundation for a new direction in the field of ALS therapy development. Incremental research does not meet the intent of this funding opportunity.

Strong Scientific Rationale: Projects that address in the intent of the mechanism should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality.

Biomarkers: Applicants are required to include consideration to biomarker(s) development in parallel with their proposed Therapeutic Idea Award research for eventual clinical trials. Efforts should be mechanism-specific and may include development of target engagement biomarkers, objective pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup, including pre-symptomatic gene carriers. Development of markers for the purposes of diagnosis, prognosis, or measurement of disease progression apart from consideration of the therapeutic development process will not be supported and instead investigators should consider the Clinical Outcomes and Biomarkers Award (HT942524ALSRPCOBA).

Funding resources
Purdue Grant Writing Lab: Introduction to Grant Writing	Open Link
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal	Open Link

Quick share

Add deadline to calendar

Jul 10, 2024 12:00:00 AM EDT

Have a funding opportunity that you want to list here?

Submit the grant details to support@peeref.com for review and listing.

Suggest reading

Canadian Institutes of Health Research Profile

Bill and Melinda Gates Foundation Profile

Empowering Innovation: A Spotlight on the National Science Foundation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Related opportunities

DoD Ovarian Cancer Research Program Pilot Award: Science and Technology and other Researc... Aug 06, 2024 12:00:00 AM EDT 4800000

DoD Ovarian Cancer, Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award: Science and Technology and other Researc... Aug 06, 2024 12:00:00 AM EDT 4800000

DoD, Melanoma, Focused Program Award - Rare Melanomas: Science and Technology and other Researc... Aug 26, 2024 12:00:00 AM EDT 6400000

DoD Peer Reviewed Orthopaedic, Women's Health Research Award: Science and Technology and other Researc... Sep 17, 2024 12:00:00 AM EDT 3000000

Support a pragmatic clinical trial programme by cancer charities: Health services, health care research 2024-09-18 €2999999

DOD Pancreatic Cancer, Focused Pilot Award: Science and Technology and other Researc... Oct 03, 2024 12:00:00 AM EDT 1280000

DoD Multiple Sclerosis, Investigator-Initiated Research Award: Science and Technology and other Researc... Oct 07, 2024 12:00:00 AM EDT 6000000

DoD Bone Marrow Failure, Investigator-Initiated Research Award: Science and Technology and other Researc... Oct 09, 2024 12:00:00 AM EDT 2440000

Market Adjustment Program: Aged Care 30-May-2025 $81,099,000.00

Strategic Prevention Framework – Partnerships for Success for States: Health Jun 05, 2025 12:00:00 AM EDT $1,250,000

Funding resources